tetano
Editor, Senior Moderator
Nat Commun
. 2021 Feb 18;12(1):1112.
doi: 10.1038/s41467-021-21310-4.
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
Alan B?nard[SUP] 1 [/SUP], Anne Jacobsen[SUP] 2 [/SUP], Maximilian Brunner[SUP] 2 [/SUP], Christian Krautz[SUP] 2 [/SUP], Bettina Kl?sch[SUP] 2 [/SUP], Izabela Swierzy[SUP] 2 [/SUP], Elisabeth Naschberger[SUP] 2 [/SUP], Malgorzata J Podolska[SUP] 2 [/SUP], Dina Kouhestani[SUP] 2 [/SUP], Paul David[SUP] 2 [/SUP], Torsten Birkholz[SUP] 3 [/SUP], Ixchel Castellanos[SUP] 3 [/SUP], Denis Trufa[SUP] 4 [/SUP], Horia Sirbu[SUP] 4 [/SUP], Marcel Vetter[SUP] 5 [/SUP], Andreas E Kremer[SUP] 5 [/SUP], Kai Hildner[SUP] 5 [/SUP], Andreas Hecker[SUP] 6 [/SUP], Fabian Edinger[SUP] 6 [/SUP], Matthias Tenbusch[SUP] 7 [/SUP], Petra M?hl-Z?rbes[SUP] 8 [/SUP], Alexander Steinkasserer[SUP] 8 [/SUP], Enrico Richter[SUP] 9 [/SUP], Hendrik Streeck[SUP] 9 [/SUP], Marc M Berger[SUP] 10 [/SUP], Thorsten Brenner[SUP] 10 [/SUP], Markus A Weigand[SUP] 11 [/SUP], Filip K Swirski[SUP] 12 [/SUP], Georg Schett[SUP] 13 [/SUP], Robert Gr?tzmann[SUP] 2 [/SUP], Georg F Weber[SUP] 14 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123[SUP]+[/SUP] epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.
. 2021 Feb 18;12(1):1112.
doi: 10.1038/s41467-021-21310-4.
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
Alan B?nard[SUP] 1 [/SUP], Anne Jacobsen[SUP] 2 [/SUP], Maximilian Brunner[SUP] 2 [/SUP], Christian Krautz[SUP] 2 [/SUP], Bettina Kl?sch[SUP] 2 [/SUP], Izabela Swierzy[SUP] 2 [/SUP], Elisabeth Naschberger[SUP] 2 [/SUP], Malgorzata J Podolska[SUP] 2 [/SUP], Dina Kouhestani[SUP] 2 [/SUP], Paul David[SUP] 2 [/SUP], Torsten Birkholz[SUP] 3 [/SUP], Ixchel Castellanos[SUP] 3 [/SUP], Denis Trufa[SUP] 4 [/SUP], Horia Sirbu[SUP] 4 [/SUP], Marcel Vetter[SUP] 5 [/SUP], Andreas E Kremer[SUP] 5 [/SUP], Kai Hildner[SUP] 5 [/SUP], Andreas Hecker[SUP] 6 [/SUP], Fabian Edinger[SUP] 6 [/SUP], Matthias Tenbusch[SUP] 7 [/SUP], Petra M?hl-Z?rbes[SUP] 8 [/SUP], Alexander Steinkasserer[SUP] 8 [/SUP], Enrico Richter[SUP] 9 [/SUP], Hendrik Streeck[SUP] 9 [/SUP], Marc M Berger[SUP] 10 [/SUP], Thorsten Brenner[SUP] 10 [/SUP], Markus A Weigand[SUP] 11 [/SUP], Filip K Swirski[SUP] 12 [/SUP], Georg Schett[SUP] 13 [/SUP], Robert Gr?tzmann[SUP] 2 [/SUP], Georg F Weber[SUP] 14 [/SUP]
Affiliations
- PMID: 33602937
- DOI: 10.1038/s41467-021-21310-4
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123[SUP]+[/SUP] epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.